Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by in situ hybridization. Mechanisms of EGFR upregulation are dependent on the ...

The researchers concluded that slower turnaround time for biomarker testing is associated with early non-targeted treatment in patients with ALK +/ EGFR + advanced NSCLC, a practice that is “common,” ...

While EGFR-TKIs have significantly improved outcomes in the 1st-line ... Japan and Russia for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, IHC 1+ ...

Although the definition of high EREG and AREG still needs to be standardized, these results suggest that high expression of these EGFR ligand genes help to select mCRC patients most likely to ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung cancer, both as monotherapy and in combination therapies. These results, ...

safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice President, Oncology Hematology R&D, AstraZeneca ...